Document is current
Any future updates will be listed below
-
Authors
Bhutani, Manisha https://orcid.org/0000-0002-9019-7438
Habib, Alma
Vegel, Andrew
Ndiaye, Ami
Struble, Emily
Shaikh, Hira
Chang, Darryl
Strouse, Christopher
Green, Kimberly M.
Graf, Kevin
Mushtaq, Muhammad Umair
Mahmoudjafari, Zahra https://orcid.org/0000-0002-3168-2521
McGuirk, Joseph P. https://orcid.org/0000-0002-0539-4796
Voorhees, Peter https://orcid.org/0000-0003-1661-718X
Khan, Abdullah Mohammad https://orcid.org/0000-0003-2166-2583
Abdallah, Al-Ola
Ahmed, Nausheen https://orcid.org/0000-0003-4336-4982
Atrash, Shebli https://orcid.org/0000-0003-4547-7534
- License Information
-
More Information
Article History
Received: 24 July 2025
Revised: 11 October 2025
Accepted: 11 November 2025
First Online: 21 November 2025
Competing interests
: MB: Consulting or Advisory Role: Caribou Biosciences; Research Funding: Janssen (Inst), Amgen (Inst), Bristol Myers Squibb/ Celgene (Inst), Takeda (Inst), Abbvie (Inst), Caribou Biosciences (Inst), and The Binding Site (Inst). KMG: Consulting or Advisory Role: Janssen, Sanofi; Research Funding: Janssen (Inst), Abbvie (Inst), Incyte (Inst), Nexcella (Inst) MUM: Research Funding: Iovance Biotherapeutics (Inst). ZM: Leadership: Hematology Oncology Pharmacists Association; Honoraria: Bristol Myers Squibb Foundation, Kite/Gilead, Genentech, Pfizer, and Sanofi. JPM: Honoraria: Kite, a Gilead company, AlloVir, Nektar, Sana Biotechnology, Bristol Myers Squibb/Sanofi, Novartis, crispr therapeutics, CARGO Therapeutics, Autolus, Legend Biotech; Consulting or Advisory Role: Kite, a Gilead company, Juno Therapeutics, Allovir, Magenta Therapeutics, EcoR1 Capital, crispr therapeutics, Fosun Kite Biotechnology Co, Ltd, Sanofi US Services, Inc, Novartis, Nektar, Sana. Biotechnology, Inc; Speakers’ Bureau: Kite/Gilead; Research Funding: Novartis (Inst), Fresenius Biotech (Inst), Astellas Pharma (Inst), Bellicum Pharmaceuticals (Inst), Novartis (Inst), Gamida Cell (Inst), Pluristem Therapeutics (Inst), Kite, a Gilead company (Inst), AlloVir (Inst). PV: Consultancy or Advisory Role: AbbVie, AstraZeneca, BMS, Karyopharm, Lava Therapeutics, Sanofi, Regeneron, Janssen, GSK; Research Funding: AbbVie, GSK, Janssen, Regeneron. A-OA: Research Funding: Celgene (Inst), Seagen (Inst), AbbVie (Inst), Bristol Myers Squibb/Medarex (Inst), Sanofi (Inst), GlaxoSmithKline (Inst). Patents, Royalties, Other Intellectual Property: PSA vaccine patent. NA: Consulting or Advisory Role: Kite/Gilead, BMS, Legend Biotech, Invivyd; Research Funding: Kite/Gilead (Inst). SA: Leadership ACCRU; Consulting or Advisory Role: Pfizer, Sanofi: Research Funding: GlaxoSmithKline, Amgen, Karyopharm Therapeutics, Janssen Oncology (Inst), Celgene/Bristol Myers Squibb (Inst); Honoraria: Janssen, GSK, Sanofi. AH, AV, AN, ES, HS, DC, CS, KG, and AMK: These authors declare no competing financial interests.
: The study protocol (DSP00000618) was approved by the Institutional Review Board (IRB) at each participating center. All methods were performed in accordance with the relevant guidelines and regulations. A waiver of informed consent was granted by the respective IRBs.
